The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant potential in clinical trials for managing obesity. Unlike some current weight loss solutions, retatrutide appears to provide a significant substantial decrease in body weight and enhance metabolic function,